vated or decreased hormone levels, subsequent examinations were performed after obtaining written informed consent. First, the patient's thyroid function tests were assayed using a modified research reagent, ruthenium was replaced by sulfonated ruthenium to reduce the effect of interfering substances, because possible interference of ruthenium or streptavidin, common components of Elecsys, was considered. As shown in Table 2 , the results showed a marked reduction of FT4 and FT3. Second, the patient's serum was measured after precipitation using streptavidin beads. The results showed no significant reduction in TSH, FT4 and FT3, which eliminated the possibility of interference with streptavidin. Third, the patient's serum was fractionated by HPLC gel filtration and thyroid function tests were measured in each fraction, as described previously [4] . When control serum was fractionated, FT4 eluted at one peak, with a molecular weight between IgG and TSH; this likely represented FT4 in equilibrium with T4 bound to plasma binding proteins. By contrast, FT3 did not elute at a clear peak but rather as an elevation of the baseline ( Fig. 1-A) . In the case of the patient's ical history was significant for rheumatoid arthritis. Laboratory tests showed mild SITSH; a normal TSH (0.52 μIU/mL; normal range: 0.5-5.0) measured by sandwich Elecsys (Roche Diagnostics K.K., Tokyo, Japan), and elevated FT4 (3.8 ng/dL; normal range: 0.9-1.6) and FT3 levels (7.6 pg/mL; normal range: 2.3-4.0) determined by competitive Elecsys. After treatment with methimazole, the patient complained of general malaise and deterioration of the goiter. Transsphenoidal surgery was recommended for a suspected TSHoma; however, the patient declined and was referred to this hospital in 2009. The methimazole was discontinued as the serum showed a normal FT4 (1.1 ng/dL), but very high TSH (19.1μIU/L). The symptoms improved one month later; however, the FT4 and FT3 increased to 3.9 ng/dL and 7.4 pg/mL, despite the normal TSH ( Table 1 ). The patient was admitted to the hospital for further evaluation.
A physical examination showed that the body temperature was 36.6 ˚C, blood pressure was 133/69 mmHg and the heart rate was 76 beats/min. The patient measured 150 cm in height and weighed 49.0 kg. Palpation revealed a mildly enlarged diffuse goiter. Mild anemia and slightly elevated hepatic transaminase levels were detected on the routine blood chemistries. Ultrasound showed a diffuse hypoechoic and moderately heterogeneous thyroid gland. Anti-thyroperoxidase antibodies were positive with a titer as low as 0.4 U/mL (normal range: <0.3 U/mL; Cosmic Co., Tokyo, Japan). The TSH receptor antibodies and anti-thyroglobulin antibodies were both negative.
For the evaluation of SITSH, magnetic resonance imaging was performed; there was no pituitary adenoma detected. Genetic analysis of the thyroid hormone receptor β gene was conducted after providing genetic counseling and obtaining written informed consent, as described previously [4] ; no mutations were identified. The institutional review board approved the study protocol. To exclude method-specific interference, the thyroid function tests were performed again using the ADVIA Centaur (Siemens, Munich, Germany) chemiluminescence assay (CLIA). The results were normal (Table 1) . Of note, four hormone levels, other than thyroid, measured by competitive Elecsys, were higher than those hormones measured by ruthenium-independent ADVIA Centaur. In addition, four other hormone levels, measured by sandwich Elecsys, were lower than the hormones measured by an alternative method (Table 1) .
To clarify the mechanism underlying the falsely ele- serum, three additional peaks of FT4 and FT3, but no TSH peak, were observed ( Fig. 1-B) . Additional peaks of thyroid hormone with a molecular weight between IgM and IgG disappeared when each fraction was measured with the modified research reagent (Fig. 1-C) . These results suggested that several substances interfered with ruthenium, which resulted in the elevation of thyroid hormone. Although the retention time of one of the common peaks of FT4 and FT3 was the same as that of IgA, at 27.0 min, only a minor part of these hormones eluted in this fraction. This excluded IgAtype antibodies from playing a major role in the interference with ruthenium. Alternately, one of the interfering substances might have had a molecular weight almost equal to that of IgA. Finally, to evaluate the frequency of similar cases, 10 subjects were recruited with serum FT4 measured by Elecsys higher than 3.2 ng/dL and TSH levels not lower than 0.5 μIU/L, among the patients presented to Ito Hospital between January 2004 and January 2011. The institutional review board approved this study. The results showed that none of the 10 subjects had anti-ruthenium interference; all of the stored serum samples had elevated FT4 determined by ruthenium-independent CLIA using Lumipulse f (Fuji Rebio Inc., Tokyo, Japan). Further examinations were not conducted in any of these additional cases.
Discussion
TSH-oma and RTH are the two main causes of SITSH; other causes, such as an ectopic TSH-producing tumor or method-specific interference, are very rare [1] [2] [3] [4] . The patient described here, was referred to us because of suspected SITSH. Further evaluation showed interfering substances against ruthenium in the Elecsys analysis. Elecsys, referred to as Eclusys in Japan, is an electrochemiluminescent immunoassay (ECLIA) involving ruthenium as the luminescent material [6] . Although this fully automated rapid assay provides prompt diagnosis of patients with thyroid disease, and has about 25% of the market share in Japan (Roche Diagnostics, personal communication, November 27, 2011), method-specific interference associated with ruthenium or streptavidin has been described previously [7] [8] [9] [10] . After Roche Diagnostics introduced improved reagents for Elecsys, in the summer of 2006, Ando and colleagues first reported antiruthenium interference in competitive Elecsys assays the interfering factor could not be identified, anti-ruthenium interference may have accounted for the erroneous results in their patient. Little information is available on substance interference with ruthenium, although anti-ruthenium antibodies have been considered (Roche Diagnostics, personal communication, November 27, 2011). Ruthenium is a rare transition metal belonging to the platinum group noted in the periodic table; it is mostly used for wearresistant electrical contacts and the production of thickfilm resistors. Bujis et al. proposed that anti-ruthenium antibodies might be induced by the intake of ruthenium in the food chain or exposure to residues on clothing [10] . For the patient reported here, the possible involvement of antibodies does not seem likely (Fig. 1) , and the specific interfering substances could not be identified.
The prevalence of "anti-ruthenium interference" remains unknown. As SITSH due to TSHoma was initially considered in this patient, it was decided to evaluate its frequency in subjects with elevated FT4 and measurable TSH. Since transient minimum hyperthyroxinemia with detectable TSH is often caused by unstable thyroid disease on treatment and since it was reported that the mean serum FT4 was 42.0 pmol/L (3.3ng/dL) in 18 patients with TSHoma [2] , the 3.2 ng/dL (i.e. 2-fold the upper limit) was interpreted as an elevated FT4. A similar interference in 10 such subjects could not be detected. A marked interference in Elecsys FT4 assays appears to be rare; however, a more mild interference might be more frequent than generally considered.
In conclusion, the mechanism associated with antiruthenium interference was examined in a patient that had elevated thyroid hormone levels due to this interference. Although similar cases appear to be rare, the case reported here raises the possibility that laboratory artifact should be considered and excluded in patients with suspected SITSH when thyroid function tests are measured by Elecsys assays.
